The standard-of-care treatment for prostate cancer is androgen deprivation therapy (ADT) which results in inhibition of androgen receptor (AR) signaling pathway and efficiently controls the growth of androgen-dependent tumors. This evidence concerns the gene AR and prostate cancer.